Background/Aims: Long non-coding RNAs (lncRNAs) have emerged as new regulators and biomarkers in several cancers. However, few lncRNAs have been well characterized in clear cell renal cell carcinoma (ccRCC). Methods: We investigated the lncRNA expression profile by microarray analysis in 5 corresponding ccRCC tissues and adjacent normal tissues. Lung cancer-associated transcript 1 (LUCAT1) expression was examined in 90 paired ccRCC tissues by real-time PCR and validated by The Cancer Genome Atlas (TCGA) database. Kaplan-Meier analysis was used to examine the prognostic value of LUCAT1 and CXCL2 in ccRCC patients. Loss and gain of function were performed to explore the effect of LUCAT1 on proliferation and invasion in ccRCC cells. Western blotting was performed to evaluate the underlying mechanisms of LUCAT1 in ccRCC progression. Chemokine stimulation assay was performed to investigate possible mechanisms controlling LUCAT1 expression in ccRCC cells. Enzyme-linked immunosorbent assays were performed to determine serum CXCL2 in ccRCC patients and healthy volunteers. Receiver operating characteristic curve analysis was performed to examine the clinical diagnostic value of serum CXCL2 in ccRCC. Results: We found that LUCAT1 was significantly upregulated in both clinical ccRCC tissues (n = 90) and TCGA ccRCC tissues (n = 448) compared with normal tissues. Statistical analysis revealed that the LUCAT1 expression level positively correlated with tumor T stage (P < 0.01), M stage (P < 0.01), and TNM stage (P < 0.01). Overall survival and disease-free survival time were significantly shorter in the high-LUCAT1-expression group than in the low-LUCAT1-expression group (log-rank P < 0.01). LUCAT1 knockdown inhibited ccRCC cell proliferation and colony formation, induced cell cycle arrest at G1 phase, and inhibited cell migration and invasion. Overexpression of LUCAT1 promoted proliferation, migration, and invasion of ccRCC cells. Mechanistic investigations showed that LUCAT1 induced cell cycle G1 arrest by regulating the expression of cyclin D1, cyclin-dependent kinase 4, and phosphorylated retinoblastoma transcriptional corepressor 1. Moreover, LUCAT1 promoted proliferation and invasion in ccRCC cells partly through inducing the phosphorylation of AKT and suppressing the phosphorylation of GSK-3β. We also revealed that chemokine CXCL2, upregulated in ccRCC, induced LUCAT1 expression and might be a diagnostic and prognostic biomarker in ccRCC. Conclusions: LUCAT1 was upregulated in ccRCC tissues and renal cancer cell lines, and significantly correlated with malignant stage and poor prognosis in ccRCC. LUCAT1 promoted proliferation and invasion in ccRCC cells through the AKT/GSK-3β signaling pathway. We also revealed that LUCAT1 overexpression was induced by chemokine CXCL2. These findings indicate that the CXCL2/LUCAT1/AKT/GSK-3β axis is a potential therapeutic target and molecular biomarker for ccRCC.
Introduction
Renal cell carcinoma (RCC) is one of the ten most common cancers, and its incidence and mortality have increased for over two decades [1] . Among the different histological types, clear cell RCC (ccRCC) is the most common subtype and accounts for approximately 70-75% of RCC [2] . Despite the widespread use of imaging in examinations, about 17% of all RCCs have distant metastases at the time of diagnosis and about 30% of patients treated for localized RCC will relapse [3, 4] . Median survival for RCC patients with metastatic disease is about 13 months [5] . However, the molecular mechanisms of RCC proliferation and invasion are still unclear. Thus, exploring possible molecular mechanisms holds great promise in management of RCC.
The discovery of non-coding RNAs (ncRNAs) in the human genome was a remarkable breakthrough in the post-genome era. Long ncRNAs (lncRNAs), one important subtype of ncRNAs, are more than 200 nucleotides long but lack protein-coding capacity [6] . Extensive research indicates that lncRNAs are aberrantly expressed in many human cancers and have comprehensive function in cancer proliferation and metastasis [7] . For example, the lncRNA metastasis-associated lung adenocarcinoma transcript 1 has been shown to be involved in proliferation and metastasis of several cancer subtypes, such as lung cancer, renal cancer, and pancreatic cancer [8] [9] [10] . The lncRNA HOX transcript antisense RNA has been shown to promote metastasis by interacting with polycomb repressive complex 2 and predict poor prognosis in breast cancer [11] . Studies have revealed that some aberrantly expressed lncRNAs are significantly associated with the prognosis of cancers, such as the lncRNAs HOXA transcript at the distal tip in hepatocellular carcinoma [12] , plasmacytoma variant translocation 1 in gastric cancer [13] , and urothelial carcinoma associated 1 in bladder cancer [14] . However, there has been relatively little research on the role of lncRNAs in ccRCC, and the overall contribution of lncRNAs to ccRCC remains largely unknown.
In this study, we performed microarray analysis to investigate the lncRNAs and proteincoding gene expression profile of ccRCC using 5 corresponding ccRCC tissues and adjacent normal tissues. The lncRNA lung cancer-associated transcript 1 (LUCAT1) [15] , one of the most upregulated lncRNAs, was overexpressed in ccRCC tissues and renal cancer cell lines and significantly correlated with malignant stage and poor prognosis in ccRCC. Our findings indicated that LUCAT1 promoted proliferation, migration, and invasion of ccRCC cells. LUCAT1 induced cell cycle G1 arrest by regulating the expression of cyclin D1, cyclin-dependent kinase 4 (CDK4), and phosphorylated retinoblastoma transcriptional corepressor 1 (p-Rb). Moreover, LUCAT1 promoted proliferation and invasion in ccRCC cells partly through the AKT/GSK-3β signaling pathway. We also revealed that LUCAT1 overexpression was induced by the chemokine CXCL2 in ccRCC. These results suggested that the CXCL2/LUCAT1/AKT/ GSK-3β axis promoted the progression of ccRCC, and might be a useful diagnostic biomarker and therapeutic target in ccRCC. For the colony formation assay, 10 3 cells were plated in each well of a 6-well plate at 48 h after RNA transfection and incubated in the corresponding medium. After one week, cells were washed twice with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 30 min, and then stained with crystal violet for 30 min for visualization and counting. All assays were performed independently 3 times using triplicate wells.
Cell wound-healing, migration, and invasion assays
To evaluate the cell migration capacity, cell wound-healing and transwell migration assays were performed. For the cell wound-healing assay, cells were seeded into 12-well plates at 48 h after RNA transfection. When cells reached 95-100% confluence, a wound was created by manually scraping the cell monolayer with a p200 pipet tip. The cells were then washed with PBS to remove cell debris and the medium replaced with serum-free medium. Images were captured by microscopy at 0 and 24 h after wounding. Transwell migration assay was performed by using transwell chamber inserts (8 μm pore size; Corning Inc., Corning, NY). Approximately 104 cells were seeded into the upper chambers in serum-free medium. For transwell invasion assay, Matrigel Invasion Chambers (8 μm) in 24-well plates (BD Bioscience, Franklin Lakes, NJ) were used and 2 × 10 5 cells were seeded into the upper chamber with serum-free medium. The lower chamber was filled with 600 μl medium with 10% FBS. After 24 h, cells in upper chambers were removed, and cells migrating to or invading the lower surface of the membrane were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of migrated or invaded cells was counted in 5 randomly selected fields under a microscope. All assays were performed independently 3 times.
Flow cytometry assay
Flow cytometry assay was performed to analyze the cell cycle and apoptosis of RCC cells. For cell cycle analysis, 2 × 10 5 cells were seeded into 6-well plates. At 48 h after siRNA transfection, cells were collected, washed with PBS, fixed with 70% ice-cold ethanol overnight, and stained with propidium iodide (PI). The cell cycle was analyzed using a FACSVerse flow cytometer (Becton Dickinson, San Jose, CA). For the apoptosis assay, cells were harvested after 48-h transfection with siRNAs. The cells were stained with annexin V-FITC and PI, according to the manufacturer's instructions. Cell apoptotic rate was determined using the FACSVerse flow cytometer. All experiments were performed independently 3 times.
Protein extraction and Western blotting
Cells were washed 3 times with ice-cold PBS and lysed in RIPA buffer (Thermo Fisher Scientific, Waltham, MA) containing protease and phosphatase inhibitor cocktail (Roche). Total protein was extracted according to the manufacturer's instructions. The protein concentration was determined using the Bio-Rad assay system (Bio-Rad Laboratories, Hercules, CA). For Western blotting analysis, equal amounts of protein extract (40 μg) were separated by electrophoresis in 10% sodium dodecyl sulfate-polyacrylamide gels and the proteins were then transferred to polyvinylidene fluoride membranes (Merck Millipore, Burlington, MA). Blotted membranes were blocked in 5% skim milk in TBST, followed by incubation with primary antibodies overnight at 4°C. The membranes were then washed 3 times for 10 min each with TBST, and subsequently incubated 1 h with horseradish peroxidase-linked secondary antibody at room temperature. GAPDH was used as the internal control. The blots were detected using an enhanced chemiluminescence kit (Merck Millipore) with a Molecular Imager system (Bio-Rad Laboratories). All experiments were performed independently 3 times.
Enzyme-linked immunosorbent assay
The level of serum CXCL2 was detected using a human CXCL2 enzyme-linked immunosorbent assay (ELISA) kit (Neobioscience Technology, China) according to the manufacturer's instructions. The serum 
Statistical analysis
Statistical analyses were performed using GraphPad Prism (version 6.0; GraphPad Software, Inc., La Jolla, CA) and SPSS (version 10.0; SPSS Inc., Chicago, IL) with P < 0.05 considered statistically significant. The significance of the differences between groups was analyzed using the Student's t test or one-way analysis of variance (ANOVA). Overall survival and disease-free survival rates were calculated using the Kaplan-Meier method with the log-rank test for comparisons. The clinical diagnostic value of serum CXCL2 was verified by receiver operating characteristic (ROC) curve analysis.
Results

Microarray expression profiling identified differentially expressed lncRNAs and mRNAs in ccRCC tissues compared with adjacent normal tissues
To investigate the potential biological functions of transcriptional changes in ccRCC, we performed microarray analysis utilizing the Human LncRNA Array v4.0 targeting 40, 916 lncRNAs and 34, 235 protein-coding genes in 5 corresponding ccRCC tissues and adjacent normal tissues (GSE96574). Unsupervised hierarchical clustering was performed to determine the lncRNA and mRNA expression profiles in ccRCC and adjacent normal tissues ( Fig. 1A and B) . We then performed volcano-plot filtering: the red plots show the upregulated lncRNAs and the green plots show the downregulated ones (Fig. 1C) . In total, we identified 1554 lncRNAs (943 upregulated and 611 downregulated) and 2504 mRNAs (1435 upregulated and 1069 downregulated) that were differentially expressed in ccRCC tissues with a fold change > 2 and P < 0.01, and the 10 most differentially expressed lncRNAs and mRNAs are listed in Table 2 . (Fig. 1D and E).
The lncRNA LUCAT1 is overexpressed in ccRCC Next, we focused on lncRNA TCONS_00010984, officially named LUCAT1, for further study. We chose LUCAT1 for several reasons. Firstly, LUCAT1 was one of the most upregulated lncRNAs in microarray analysis and validation. Secondly, LUCAT1 expression positively correlated with aggressive stage in both the Sun Yat-sen cohort and TCGA cohort. Lastly, functional pre-experiments indicated that LUCAT1 acts as an oncogene in ccRCC.
To explore the role of LUCAT1 in ccRCC progression, we first examined LUC-AT1 expression in 90 paired ccRCC tissues and adjacent normal tissues by RT-PCR. We found that LUCAT1 was upregulated in ccRCC tissues compared with adjacent normal tissues (P < 0.01) ( Fig. 2A) . Consistent with this result, LUCAT1 was found to be overexpressed in ccRCC tissues compared with normal tissues in another independent cohort of 448 ccRCC samples and 67 normal samples available at TCGA database (P < 0.01) (Fig. 2B and C) . We further examined the expression level of LUCAT1 in ccRCC cell lines (786-O, Caki-1, Caki-2, ACHN, 769-P, and A-498) and one normal kidney cell line (HK-2) by RT-PCR, using β-actin as a reference gene. We found that the LUCAT1 expression was significantly higher in ccRCC cell lines than in HK-2, which confirmed that LUCAT1 could be a potential oncogene in ccRCC and its expression might correlate with malignancy (Fig. 2D) (Table 3) . To further validate the association between LUCAT1 expression level and the clinical characteristics of ccRCC patients, LUCAT1 RNA-Seq expression values and relevant clinical information of 448 TCGA ccRCC patients were downloaded from TCGA and TANRIC websites and statistical analysis was performed. The results showed that LUCAT1 expression significantly correlated with T stage (P < 0.01), M stage (P < 0.01), and TNM stage (P < 0.01) ( Table 3) .
LUCAT1 expression predicts prognosis of ccRCC patients
To identify the prognostic value of LUCAT1, we examined the correlation between LUCAT1 expression and prognosis using the Kaplan-Meier method. ccRCC patients in TCGA database were divided into a high-LUCAT1-expression group (n = 224) and low-LUCAT1-expression group (n = 224) by the median expression level. The Kaplan-Meier analysis showed that overall survival and disease-free survival time were significantly shorter in the high-LUCAT1-expression group than in the low group (log-rank P < 0.01) (Fig. 2E and F) . To further evaluate the prognostic value of LUCAT1 in ccRCC, we carried out univariate analysis using age, gender, tumor size, T stage, N stage, M stage, and LUCAT1 expression. The result revealed that LUCAT1 expression was an independent predictor of overall survival (Table  4) . Taken together, these data suggested that LUCAT1 might play an important role in ccRCC progression and act as an unfavorable prognostic factor.
LUCAT1 knockdown inhibits proliferation, migration, and invasion of ccRCC cells
To investigate the subcellular localization of LUCAT1 in ccRCC cells, we isolated total RNA from nuclear and cytosolic fractions of Caki-2 and 786-O. RT-PCR was performed to measure LUCAT1 expression in both fractions. U6 is known to be a nuclear localized RNA and GAPDH, a protein-coding mRNA, was expected in the cytoplasm. The result showed that LUCAT1 was preferentially located in the nucleus (Fig. 3A) . To evaluate the role of LUCAT1 in ccRCC progression, siRNAs were designed to knock down LUCAT1. The RT-PCR results showed that LUCAT1 was significantly downregulated by siRNA#1 (si#1) and siRNA#2 (si#2) in two ccRCC cell lines, Caki-2 and 786-O (Fig. 3B) . Colony formation assays were employed to examine the effect of LUCAT1 on cell growth of ccRCC. The results indicated that LUCAT1 knockdown significantly inhibited the proliferation and colony formation of 786-O and Caki-2 ( Fig. 3C and D) . The effect of LUCAT1 on the cell cycle was observed by flow cytometry. Compared with the negative control, LUCAT1 knockdown significantly increased the percentage of cells in G1 phase and decreased the percentage of cells in S phase (Fig. 3E) . Additionally, apoptosis assay by flow cytometry was employed and no significant difference was found. To support the flow cytometry results, Western blotting was performed to measure the G1/S cell cycle checkpoint-related proteins. The result showed that the expression of cyclin D1, CDK4, and p-Rb was decreased after LUCAT1 knockdown, while cyclin E2 and CDK2 showed no obvious changes (Fig. 3F) .
We further evaluated the effects of LUCAT1 on ccRCC cell migration and invasion. The wound-healing assay revealed that LUCAT1 knockdown inhibited cell mobility in both 786-O and Caki-2 (Fig. 4A) . The transwell migration assay demonstrated that downregulation of LUCAT1 significantly reduced the migration of both 786-O and Caki-2 (Fig.  4B) . Furthermore, LUCAT1 knockdown significantly reduced the invasive potential of ccRCC cells in a transwell invasion assay (Fig. 4B) . Thus, these results suggested that LUCAT1 knockdown inhibited the migration and invasive ability of ccRCC cells.
LUCAT1 overexpression promotes proliferation, migration, and invasion of ccRCC cells
We overexpressed LUCAT1 in ccRCC cells by lentivirus vector-mediated overexpression. The expression level of LUCAT1 in 786-O and Caki-2 was significantly increased after transfection with pLV-LUCAT1 compared with the negative control (pLV-NC) (Fig. 5 A) . Colony formation assays were employed to examine the growth of ccRCC cells. The results indicated that LUCAT1 overexpression significantly promoted the proliferation and colony formation of 786-O and Caki-2 ( Fig. 5B and C) . Flow cytometry analysis showed that LUCAT1 overexpression significantly increased the percentage of cells in S phase and decreased the percentage of cells in G1 phase (Fig. 5D) . The transwell migration and invasion assays demonstrated that LUCAT1 overexpression significantly promoted the migration and invasive ability in both 786-O and Caki-2 (Fig. 5E) . Together, these results showed that LUCAT1 overexpression promoted proliferation, migration, and invasion of ccRCC cells. 
LUCAT1 regulates the progression of ccRCC through the AKT/GSK-3β signaling pathway
In order to explore the possible molecular mechanism of LUCAT1's effects, we performed gene set enrichment analysis (GSEA) to identify associated pathways in ccRCC. We compared the gene expression profile between high LUCAT1 expression M1 ccRCC patients with low LUCAT1 expression M0 ccRCC patients in TCGA database. Several cancer-related pathways such as the NF-kB pathway, AKT pathway, and P53 pathway were enriched (Fig. 6A) . We performed Western blotting to analyze key proteins of these pathways, and the results showed that p-AKT expression was significantly decreased after LUCAT1 knockdown, while P53 and NF-kB showed no significant change. We further examined the key downstream components of the AKT pathway, including p-GSK-3β, β-catenin, and p-mTOR. The results showed that p-GSK-3β expression was significantly increased after LUCAT1 knockdown (Fig. 6B) . A similar result was found in the LUCAT11 overexpression experiment (Fig. 6C) . In order to confirm the important role of the AKT pathway in ccRCC, we overexpressed LUCAT1 in ccRCC cells and concomitantly inhibited the AKT pathway using LY294002. The result showed that inhibition of the AKT pathway significantly reduced the effects of LUCAT1 on the invasive ability of ccRCC cells (Fig. 6D) . Therefore, these results suggested that LUCAT1 regulated the progression of ccRCC through the AKT/GSK-3β signaling pathway.
LUCAT1 is regulated by CXCL2 in ccRCC cells
Next, we investigated the possible mechanisms controlling LUCAT1 expression in ccRCC cells. Previous research suggested that chemokines or cytokines released by immune cells could regulate the expression of lncRNAs in cancer cells [18] . We performed a computational screen by analyzing the correlation between LUCAT1 and chemokines or cytokines using TANRIC. We found that LUCAT1 expression was significantly correlated with chemokine CXCL2 and CXCL8 and cytokine IL-6 mRNA expression in ccRCC tissues (Fig. 7A) . We next determined whether LUCAT1 expression in ccRCC cells was mediated by CXCL2, CXCL8, or IL-6. Caki-2 and 786-O were exposed to CXCL2, CXCL8, and IL-6 at different concentrations for 48 h. The results showed that CXCL2 significantly increased the expression of LUCAT1 in ccRCC cells (Fig. 7B) . No significant difference was found with CXCL8 or IL-6 stimulation. We then treated Caki-2 and 786-O with 50 ng/ml CXCL2 for various times and the results also showed that CXCL2 significantly increased the expression of LUCAT1 in ccRCC cells (Fig. 7C) . However, LUCAT1 knockdown did not make a difference in CXCL2 expression in ccRCC cells (Fig. 7D ). In addition, we analyzed CXCL2 expression between ccRCC tissues and normal tissues using gene expression profiling and interactive analysis (GEPIA). We found that CXCL2 was significantly upregulated in ccRCC tissues (n = 523) compared with normal tissues (n = 100) (Fig. 7E) . The Kaplan-Meier survival analysis revealed that ccRCC patients with higher CXCL2 expression have a shorter overall survival time (Fig. 7F) . We also analyzed the serum CXCL2 level in ccRCC patients (n = 60) and healthy volunteers (n = 20), and found that serum CXCL2 expression in ccRCC patients was significantly higher than in healthy volunteers (Fig. 7G) . ROC curve analysis revealed that serum CXCL2 level might be a diagnostic biomarker (AUC = 0.868) for ccRCC (Fig. 7H) . In summary, these results showed that the expression of LUCAT1 was regulated by CXCL2 in ccRCC cells. These data, along with the above knockdown and overexpression experiments, indicated that CXCL2 in tumor microenvironments, synthesized and secreted by immune cells, induced LUCAT1 expression and promoted proliferation and invasion in ccRCC (Fig. 8) . 
Discussion
It has been demonstrated that the human transcriptome comprises not only proteincoding RNAs but also a large number of ncRNAs, including lncRNAs [19] . lncRNAs are emerging as functional regulators in various cancer processes, including proliferation, invasion, and metastasis [8, 20, 21] . However, few lncRNAs have been well characterized in ccRCC. In this study, we used microarray analysis and found that 943 lncRNAs are upregulated and 611 lncRNAs are downregulated (fold change > 2 and P < 0.01) in ccRCC.
Among these lncRNAs, LUCAT1, located at chromosome 5q14.3, has been found to be associated with poor prognosis in non-small cell lung cancer and promotes cell proliferation via regulating p21 and p57 expression [22] . In this study, we found that LUCAT1 was overexpressed in ccRCC tissues and cell lines compared with adjacent normal tissues and a normal kidney epithelial cell line. We also analyzed the association between LUCAT1 expression and clinical characteristics of ccRCC patients. We found that the LUCAT1 expression significantly correlated with T stage, M stage, and TNM stage. The prognostic value of LUCAT1 in ccRCC was also analyzed using the Kaplan-Meier method and we found that LUCAT1 expression was significantly associated with the overall survival and diseasefree survival of ccRCC patients. ccRCC patients with high LUCAT1 expression had poorer survival than those with low LUCAT1 expression. To the best of our knowledge, this is the first report showing that LUCAT1 might be a predictor of survival in ccRCC patients.
The unlimited proliferation of cancer cells is often due to disorders of the cell cycle [23, 24] . Our research team previously reported that knockdown of lncRNA AATBC resulted in inhibited bladder cancer cell proliferation through cell cycle arrest [25] . The G1/S cell cycle checkpoint, the major regulatory checkpoint, controls progression of cells through the restriction point into the S-phase [26] . The cyclin D1-CDK4 complex contributes to the progression of cells through the G1/S cell cycle checkpoint via increasing phosphorylation of Rb [27] . In the present study, the cell proliferation assay, colony formation assay, and flow cytometry analysis demonstrated that LUCAT1 promoted ccRCC cell proliferation and increased the percentage of cells in S phase. Western blot provided molecular evidence supporting these observations. The results showed that the expression of cyclin D1, CDK4, and p-Rb was decreased after LUCAT1 knockdown. Therefore, the most likely mechanism underlying the proliferation regulation involves inhibiting the cyclin D1-CDK4 complex, and then ultimately inducing cell cycle arrest at the G1 phase.
As LUCAT1 expression significantly correlated with T stage and M stage, we suspected that LUCAT1 could play an important role in ccRCC metastasis. We therefore determined whether LUCAT1 expression influenced ccRCC migration and invasion. The wound-healing and transwell migration and invasion assays demonstrated that LUCAT1 promoted migration and invasive ability of ccRCC cells. These results suggested that LUCAT1 could promote ccRCC metastasis by affecting migration and invasion.
Aberrant AKT and Wnt pathways contribute to cell proliferation and metastasis in many kinds of cancers [28, 29] . The interaction between the two pathways through the AKT/GSK-3β axis has been found to participate in the progression of ccRCC [30] . AKT phosphorylation can inhibit the activity of GSK-3β, which plays a vital role in β-catenin phosphorylation and degradation, and activate the transcription of downstream target oncogenes such as cyclin D1 [31, 32] . In our research, LUCAT1 knockdown reduced the expression level of p-AKT and activated GSK-3β, resulting in the downregulation of β-catenin and cyclin D1. Moreover, LUCAT1 overexpression significantly promoted AKT phosphorylation and then inhibited the activity of GSK-3β, and ultimately promoted the progression of ccRCC. Therefore, these results suggested that the molecular mechanism underlying LUCAT1's ability to induce proliferation and invasion in ccRCC might depend on the activation of the AKT/GSK-3β signaling pathway.
We further explored the possible mechanisms underlying how LUCAT1 expression is dysregulated in ccRCC. Computational screen and stimulation assay revealed that the chemokine CXCL2 induced LUCAT1 expression in ccRCC cells. In addition, serum CXCL2 expression in ccRCC patients is significantly higher than in healthy volunteers and ccRCC Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry patients with higher CXCL2 expression have a shorter overall survival time. To the best of our knowledge, CXCL2 is mainly synthesized and secreted by macrophages or other immune cells that could promote cancer progression and metastasis by releasing a variety of chemokines [33, 34] . Therefore, one possible mechanism regulating LUCAT1 expression in ccRCC is that CXCL2 in the tumor microenvironment, synthesized and secreted by macrophages or other immune cells, bound to a specific transmembrane receptor on ccRCC cells and induced LUCAT1 expression. The upregulation of LUCAT1 promoted the phosphorylation of AKT and then inhibited the activity of GSK-3β. On one hand, inhibition of GSK-3β reduced the degradation of β-catenin and promoted invasion of ccRCC. On the other hand, inhibition of GSK-3β reduced the degradation of cell cycle-related proteins, such as cyclin D1, and facilitated proliferation of ccRCC. Our study highlights the importance of the tumor microenvironment in the progression of ccRCC and it is worthy of further research.
In conclusion, we found that LUCAT1 was upregulated in ccRCC tissues and renal cancer cell lines, and significantly correlated with malignant stage and prognosis in ccRCC. LUCAT1 promoted proliferation and invasion of ccRCC cells partly through the AKT/GSK-3β signaling pathway. We also revealed that LUCAT1 overexpression was induced by the chemokine CXCL2. These results suggest that the CXCL2/LUCAT1/AKT/GSK-3β axis plays a critical role in promoting the progression of ccRCC, and might be a useful diagnostic biomarker and therapeutic target in ccRCC.
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